PDS Biotechnology Corp's President and CEO, BEDU-ADDO FRANK, has reported significant stock option transactions in a recent SEC filing. This move is crucial for the company as it seeks to align the interests of its leadership with the long-term goals of the organization.

On November 17, 2026, the company filed a Form 4 with the SEC, detailing the acquisition of over 19 million shares through employee stock options. The options were granted at an exercise price of $0.9241, and the filing indicates that these options are contingent upon stockholder approval of the company’s 2026 Equity Incentive Plan.

Background

PDS Biotechnology Corp, incorporated in Delaware, operates in the pharmaceutical preparations sector. The company's focus is on developing innovative therapies to treat various diseases. The recent filing is part of a series of transactions reported by BEDU-ADDO FRANK, highlighting ongoing efforts to incentivize leadership within the company.

What the Filing Says

The SEC filing states, "The option was granted on November 16, 2026, subject to stockholder approval of the Issuer's 2026 Equity Incentive Plan under Nasdaq Marketplace Rule 5635(c)." It also notes that the options are not exercisable until stockholder approval is obtained.

Impact

This filing may affect PDS Biotechnology's employees and stakeholders, particularly as the options are designed to motivate and retain key executives. The approval of the equity incentive plan will be crucial for the company’s strategy moving forward, potentially influencing employee morale and performance.

What's Next

Details regarding the timeline for stockholder approval were not available in the SEC filing.